Patent & Trade Mark
Attorneys
We are
Experts in Navigating IP in the Asia Pacific Region
Working with clients in
Thanks to many years of global experience, FB Rice has a network of trusted advisors in all key jurisdictions. We turn to those advisors when assisting our clients to promote their interests.

For specific information on our Asia Pacific capability, click here.
One door to South East Asia
For a seamless service for filing and prosecuting patent and trade mark applications in South East Asia, click here.
Rachel Hooke

Partner

Rachel Hooke
“The importance of innovation in the medical technology is growing and FB Rice is here to help our clients protect their investment in research.”
“The importance of innovation in the medical technology is growing and FB Rice is here to help our clients protect their investment in research.”
Australia: Change to patent examiners manual creates uncertainty
It is a long-standing principle of Australian patent law that determining whether or not a patent application is directed towards patentable subject matter should be done separately to determining issues of novelty and inventive step. However, amendments to the Australian Patent Examiners Manual late last year introduced a new practice, encouraging consideration of prior art when assessing subject matter eligibility, which in Australia includes the requirement that the invention be a manner of manufacture.
It is a long-standing principle of Australian patent law that determining whether or not a patent application is directed towards patentable subject matter should be done separately to determining issues of novelty and inventive step. However, amendments to the Australian Patent Examiners Manual late last year introduced a new practice, encouraging consideration of prior art when assessing subject matter eligibility, which in Australia includes the requirement that the invention be a manner of manufacture.
16 September 2017
FB Rice supports Marriage Equality in Australia
At FB Rice, we recognise that diversity is a strength and that we are a better firm for having people with different ethnicity, sex, gender identity, sexual orientation and backgrounds.
At FB Rice, we recognise that diversity is a strength and that we are a better firm for having people with different ethnicity, sex, gender identity, sexual orientation and backgrounds.
Lisa Neilson

Associate

Lisa Neilson
Lisa is a Trade Marks Associate in our Sydney office and joined the firm in 2009. Lisa’s practice covers all aspects of trade mark registration, protection and enforcement in Australia and New Zealand including prosecution, oppositions and non-use removal actions. Lisa has extensive experience managing global trade mark portfolios, advising on local and global filing strategies and with all aspects of the Madrid System for the International Registration of trade marks.
Lisa is a Trade Marks Associate in our Sydney office and joined the firm in 2009. Lisa’s practice covers all aspects of trade mark registration, protection and enforcement in Australia and New Zealand including prosecution, oppositions and non-use removal actions. Lisa has extensive experience managing global trade mark portfolios, advising on local and global filing strategies and with all aspects of the Madrid System for the International Registration of trade marks.
09 March 2018
New Zealand patent regulations amended to fix filing issues
From 5 April 2018, various amendments to the Patents Regulations 2014 come into effect in New Zealand to address a few unintended problems arising from the new Patents Act 2013 and its Regulations. Issues being fixed include addressing filing requirements around divisional claims and microorganism deposits.
From 5 April 2018, various amendments to the Patents Regulations 2014 come into effect in New Zealand to address a few unintended problems arising from the new Patents Act 2013 and its Regulations. Issues being fixed include addressing filing requirements around divisional claims and microorganism deposits.
Expect the unexpected | Patenting antibodies in Asia
Monoclonal antibodies are important human therapeutic agents and represent some of the largest selling drugs in the world. Patents relating to antibodies are treated differently to some other compounds in some jurisdictions. This article touches on some of the important requirements for antibody patenting in some major Asian jurisdictions, namely Japan, China and South Korea.
Monoclonal antibodies are important human therapeutic agents and represent some of the largest selling drugs in the world. Patents relating to antibodies are treated differently to some other compounds in some jurisdictions. This article touches on some of the important requirements for antibody patenting in some major Asian jurisdictions, namely Japan, China and South Korea.